ActoGeniX N.V. Patent applications |
Patent application number | Title | Published |
20140322266 | INDUCTION OF MUCOSAL TOLERANCE TO ANTIGENS - The present invention relates to the induction of tolerance to antigens, by mucosal, preferably oral delivery of the antigen in combination with an immunomodulating compound producing micro-organism. More specifically, the invention relates to the induction of Foxp3 | 10-30-2014 |
20140322230 | INDUCTION OF MUCOSAL TOLERANCE TO ANTIGENS - The present invention relates to the induction of tolerance to antigens, by mucosal, preferably oral delivery of the antigen in combination with an immunomodulating compound producing micro-organism. More specifically, the invention relates to the induction of Foxp3 | 10-30-2014 |
20140105863 | POLYCISTRONIC EXPRESSION SYSTEM FOR BACTERIA - The invention relates to polycistronic expression in gram-positive bacterium and in particular concerns polycistronic expression units comprising one or more gene endogenous to the gram-positive bacterium transcriptionally coupled to one or more genes exogenous to the bacterium. | 04-17-2014 |
20130330374 | TREATMENT OF IMMUNE DISEASE BY MUCOSAL DELIVERY OF ANTIGENS USING GENETICALLY MODIFIED LACTOBACILLUS - The present invention relates to the treatment of autoimmune and allergic diseases by mucosal delivery by micro-organism, in particular | 12-12-2013 |
20130164380 | COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY CONDITIONS - The present invention provides methods and compositions for treating inflammatory bowel disease, including ulcerative colitis and Crohn's Disease, and other related conditions, by locally administering to the intestinal mucosa of a subject having inflammatory bowel disease a therapeutically effective amount of IL-27 or a therapeutic variant or fragment thereof. The invention further provides a method to treat inflammatory bowel disease comprising administering to the subject a recombinant microorganism capable of producing a therapeutically effective amount of IL-27 or a variant or fragment thereof in situ in the intestinal mucosa. | 06-27-2013 |
20130095129 | TREATMENT OF IMMUNE DISEASE BY MUCOSAL DELIVERY OF ANTIGENS USING GENETICALLY MODIFIED LACTOBACILLUS - The present invention relates to the treatment of autoimmune and allergic diseases by mucosal delivery by micro-organism, in particular | 04-18-2013 |
20120183503 | LACTOBACILLUS AND STREPTOCOCCUS PROMOTERS AND USES THEREOF - The invention is in the field of molecular biology, and relates to recombinant engineering and protein expression. More in particular, the invention relates to nucleic acids for recombinant expression of proteins comprising sequences derived from | 07-19-2012 |
20120039853 | CRYOPROTECTANTS FOR FREEZE DRYING OF LACTIC ACID BACTERIA - The present invention comprises the discovery and development of an effective cryoprotectant composition, without containing skim milk or any other animal-derived compounds, to achieve long-term stability of freeze-dried lactic acid bacteria (LAB), at different temperatures, whereby the retention of viability of the freeze-dried LAB after 6 months of storage, preferably after 9 months of storage, more preferably after 12 months of storage is more than 50%. The invention is in the field of producing freeze dried bacteria, in particular Lactic acid bacteria. More in particular, the invention relates to the use of a novel combination of cryoprotectants for increasing the viability of bacteria after freeze drying, improving the texture of the lyofilized cake for easy grinding and improving the long term stability of the freeze dried bacteria at different temperature conditions. The invention further relates to such freeze dried bacteria for use in food industry or in human or animal health applications. More in particular, the invention relates to the increased viability and long-term storage of recombinant bacteria capable of expressing heterologous proteins or peptides and administered to humans or animals for therapeutic or vaccination purposes. | 02-16-2012 |
20100303777 | DELIVERY OF BINDING MOLECULES TO INDUCE IMMUNOMODULATION - Delivery of binding molecules, such as antibodies, antibody fragments, single antibody variable domains, soluble receptors, ligands and dominant negative variants, to induce an immunomodulation in a patient is disclosed. More specifically, a medicament which includes micro-organisms which produce the binding molecules is described for the treatment of immune mediated diseases. | 12-02-2010 |
20100172920 | METHOD OF INDUCING IMMUNE TOLERANCE TO TYPE I DIABETES - A method for inducing immune tolerance to type I diabetes in a mammal by mucosal delivery of an antigen involved in the induction of type I diabetes such as pro-insulin or insulin is disclosed. The antigen involved in the induction of type I diabetes is delivered together with an IL-10 secreting micro-organism such as | 07-08-2010 |
20100080774 | LACTOCOCCUS PROMOTERS AND USES THEREOF - The invention is in the field of molecular biology, and relates to recombinant engineering and protein expression. More in particular, the invention relates to nucleic acids for recombinant expression of proteins comprising sequences derived from | 04-01-2010 |
20090148389 | INDUCTION OF MUCOSAL TOLERANCE TO ANTIGENS - Induction of tolerance to antigens by mucosal, preferably oral, delivery of the antigen in combination with an immunomodulating compound producing micro-organism is disclosed. More specifically, Foxp3 | 06-11-2009 |
20090074734 | MICROBIAL INTESTINAL DELIVERY OF OBESITY RELATED PEPTIDES - Microbial delivery of obesity related peptides is disclosed. Genetically modified yeasts and/or lactic acid bacteria are described for the delivery of neuropeptides and/or peptide hormones that play a role in stimulation or inhibition of food intake and/or energy homeostasis. | 03-19-2009 |
20080274084 | Anti-Tnf Alpha Producing Lactic Acid Bacteria for the Treatment of Chronic Enterocolitis - Treatments for chronic enterocolitis are disclosed. More specifically, methods for administration of pharmaceutical compositions that include anti-TNF-alpha antibody producing lactic acid microorganisms, such as | 11-06-2008 |